evo756
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 14, 2024 (NCT06603220)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
MRGPRX2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07150845 | Phase 2 | Aug 26, 2025 | Evommune, Inc. |
| NCT06873516 | Phase 2 | Mar 31, 2025 | Evommune, Inc. |
| NCT06603220 | Phase 2 | Aug 14, 2024 | Evommune, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Evommune, Inc. | For profit | 3 | 3 | 1 | 2024 |
1 organizations
Page 1 / 1